Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.29
-$0.11(-1.36%)
At close: 4:00 PM EST
$7.29
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.73 - $9.54
Previous CloseN/A
Volume82.15K
Average Volume (3M)651.49K
Market Cap
$723.02M
Enterprise Value$353.48
Total Cash (Recent Filing)$114.73M
Total Debt (Recent Filing)$16.99M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding103,436,420
10 Day Avg. Volume610,944
30 Day Avg. Volume651,491
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.50Price Target Upside222.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe ~$280.8M equity raise materially extends funding into the second half of 2028, enabling completion of registration‑enabling activities and Phase 3 enrollment without immediate refinancing. This durability reduces near‑term execution risk and supports long‑lead drug development milestones.
Low LeverageModest debt relative to equity provides financial flexibility for a clinical‑stage biotech, lowering bankruptcy and interest burden risk. Even as equity has eroded, limited leverage preserves optionality for partnership, milestone payments, or targeted capital raises without heavy debt servicing constraints.
Stronger Leadership & GovernanceRecent CEO appointment and addition of a director with rare oncology commercialization track record bolster operational and regulatory experience. This governance strengthening improves odds of effective late‑stage execution, strategic partnering, and commercialization planning ahead of potential approval events.
Bears Say
Pre‑Revenue ProfileThe company remains pre‑revenue, meaning value realization hinges on successful clinical outcomes and commercialization. Without product sales, long‑term sustainability requires capital markets or partners; failure to achieve approvals or commercial traction would leave the firm structurally dependent on external funding.
Persistent Cash BurnOperating and free cash flow have deteriorated meaningfully, rising from roughly -$32M in 2021 to -$91M TTM. This structural burn rate creates ongoing funding requirements and increases dilution or partnership dependency risk until revenue generation or sustained cost reductions occur.
Single‑Asset Clinical ConcentrationBusiness is heavily dependent on bel‑sar's clinical success; Phase 3 topline is projected in H2 2027. This single‑asset concentration creates binary downside risk—adverse trial results or regulatory setbacks would materially impair revenue prospects and force strategic pivots or accelerated capital raises.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.73 and its highest was $9.54 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $723.02M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.398 by -$0.102.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.38.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 103,436,420 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.398. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (222.36% Upside)
$23.50 (222.36% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 83.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 40.0%
Last 30 Days ▲ 40.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA Stock 12 Month Forecast
Average Price Target
$23.50
▲(222.36% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.20% Insiders
5.22% Mutual Funds
33.37% Other Institutional Investors
50.39% Public Companies and
Individual Investors